These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 2856188)

  • 1. Antithrombotic effects of the thromboxane A2 antagonist, SQ 28,668, in vitro and in the coronary circulation in vivo.
    Ogletree ML; Harris DN; Heran CL; Phillips MB; Michel IM; Goldenberg HJ
    Eicosanoids; 1988; 1(2):85-91. PubMed ID: 2856188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protamine-induced pulmonary hypertension in heparinized monkeys and pigs is inhibited by the thromboxane receptor antagonist SQ 30,741.
    Schumacher WA; Heran CL; Ogletree ML
    Eicosanoids; 1990; 3(2):87-93. PubMed ID: 2144979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined administration of 5-HT2 and thromboxane A2 antagonists: effects on platelet aggregation and isolated cardiac muscle.
    Shaw LA; Batey AJ; Coker SJ
    Br J Pharmacol; 1997 Jul; 121(5):875-82. PubMed ID: 9222543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane receptor activation during bronchospasm induced by platelet-activating factor.
    Schumacher WA; Steinbacher TE
    J Lipid Mediat; 1991; 4(1):97-110. PubMed ID: 1832573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of thromboxane receptor antagonists on renal artery thrombosis in the cynomolgus monkey.
    Schumacher WA; Goldenberg HJ; Harris DN; Ogletree ML
    J Pharmacol Exp Ther; 1987 Nov; 243(2):460-6. PubMed ID: 2960794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of the short-acting thromboxane receptor antagonist, SQ 30,741, in thrombolytic and vasospastic models in monkeys.
    Schumacher WA; Heran CL; Hartl KS; Ogletree ML
    J Pharmacol Exp Ther; 1990 May; 253(2):841-6. PubMed ID: 2140131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
    Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet reactivity in vitro in relation to thromboxane in healthy pregnancy.
    Horn EH; Hardy E; Cooper J; Heptinstall S; Rubin PC
    Thromb Haemost; 1996 Feb; 75(2):346-51. PubMed ID: 8815588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of trapidil derivatives on arachidonic acid- and prostaglandin endoperoxide analogue- induced platelet aggregation and thromboxane A2 formation.
    Heinroth I; Block HU; Mest HJ
    Biomed Biochim Acta; 1984; 43(8-9):S389-92. PubMed ID: 6440555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
    Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.
    Harris DN; Michel IM; Goldenberg HJ; Hartl KS; Allen GT; Steinbacher TE; Schumacher WA; Han WC; Hall SE; Floyd DM
    J Pharmacol Exp Ther; 1992 Apr; 261(1):131-7. PubMed ID: 1532833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct myocardial effects of the thromboxane A2/prostaglandin H2 agonists U-46619 and SQ 26,655 under ischemic and nonischemic conditions.
    Grover GJ; Hedberg A; Ogletree ML
    Pharmacology; 1990; 41(1):1-15. PubMed ID: 2122481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury.
    Simpson PJ; Smith CB; Rosenthal G; Lucchesi BR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):497-501. PubMed ID: 3735129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion.
    Grover GJ; Schumacher WA; Simon M; Parham C
    J Cardiovasc Pharmacol; 1988 Dec; 12(6):701-9. PubMed ID: 2467089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve.
    Grover GJ; Schumacher WA
    J Pharmacol Exp Ther; 1989 Feb; 248(2):484-91. PubMed ID: 2521899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries.
    Tanaka T; Morishima Y; Watanabe K; Takahashi M; Shibano T
    Methods Find Exp Clin Pharmacol; 1995 Dec; 17(10):693-700. PubMed ID: 9053590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.